The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2018 | The potential of anti-amyloid antibodies to treat amyloidosis
Dr Suzanne Lentzsch, MD, PhD, of Columbia University, New York, NY, presents data from the latest clinical trials testing drugs for amyloidosis. Lentzsch reports on an ongoing study that compares the efficacy of CyBorD vs CyBorD combined with daratumumab, results of which could greatly influence treatment approaches for Amyloidosis in the near future. From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Dr Lentzsch emphasizes the need for more research on anti-amyloid antibodies, highlighting the recent success of FDA-approved drug tafamidis, which significantly increased overall survival in patients with amyloidosis.
